Brexi0.5 mg

Brexi 0.5 mg is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Treatment of schizophrenia

Benzodiazepine antagonist

The mechanism of action of Brexi 0.5 mg in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of Brexi 0.5 mg may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.

Adjunctive Treatment of Major Depressive Disorder: The recommended starting dosage for Brexi 0.5 mg as adjunctive treatment is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment.Treatment of Schizophrenia: The recommended starting dosage for Brexi 0.5 mg is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Brexi 0.5 mg dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 4 mg.

Adjunctive Treatment of Major Depressive Disorder: The recommended starting dosage for Brexi 0.5 mg as adjunctive treatment is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for treatment.Treatment of Schizophrenia: The recommended starting dosage for Brexi 0.5 mg is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Brexi 0.5 mg dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 4 mg.

Brexi 0.5 mg is contraindicated in patients with a known hypersensitivity to Brexi 0.5 mg or any of its components. Reactions have included rash, facial swelling, urticaria, and anaphylaxis.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Brexi 0.5 mg during pregnancy. Lactation studies have not been conducted to assess the presence of Brexi 0.5 mg in human milk, the effects of Brexi 0.5 mg on the breastfed infant, or the effects of Brexi 0.5 mg on milk production. Brexi 0.5 mg is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Brexi 0.5 mg and any potential adverse effects on the breastfed infant from Brexi 0.5 mg or from the underlying maternal condition.

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia- Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring Tardive Dyskinesia: Discontinue if clinically appropriate Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain Pathological Gambling and Other Compulsive Behaviors: Consider dose reduction or discontinuation Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Brexi 0.5 mg if a clinically significant decline in WBC occurs in absence of other causative factors Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold

Store Brexi 0.5 mg tablets at 20°C to 25°C; excursions permitted to 15°C to 30°C

Dosage Adjustments for Hepatic Impairment: For patients with moderate to severe hepatic impairment, the maximum recommended dosage is 2 mg once daily for patients with MDD, and 3 mg once daily for patients with schizophreniaDosage Adjustments for Renal Impairment: For patients with moderate, severe or end-stage renal impairment (creatinine clearance ClCr<60 mL/minute), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophreniaPediatric Use: Safety and effectiveness in pediatric patients have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients Geriatric Use: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, and cardiac function, concomitant diseases, and other drug therapy.

Benzodiazepine antagonist

The mechanism of action of Brexi 0.5 mg in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of Brexi 0.5 mg may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Brexi 0.5 mg during pregnancy. Lactation studies have not been conducted to assess the presence of Brexi 0.5 mg in human milk, the effects of Brexi 0.5 mg on the breastfed infant, or the effects of Brexi 0.5 mg on milk production. Brexi 0.5 mg is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Brexi 0.5 mg and any potential adverse effects on the breastfed infant from Brexi 0.5 mg or from the underlying maternal condition.

Dosage Adjustments for Hepatic Impairment: For patients with moderate to severe hepatic impairment, the maximum recommended dosage is 2 mg once daily for patients with MDD, and 3 mg once daily for patients with schizophreniaDosage Adjustments for Renal Impairment: For patients with moderate, severe or end-stage renal impairment (creatinine clearance ClCr<60 mL/minute), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophreniaPediatric Use: Safety and effectiveness in pediatric patients have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients Geriatric Use: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, and cardiac function, concomitant diseases, and other drug therapy.